Drugs / NEUK203-215
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07144462 | Sep 2025 → Jan 2027 expected | autoimmune disease | Neukio Biotherapeutics (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEUK203-215 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07144462 ↗ |
| Modality | Cell therapy | “a healthy donor (HD) allogeneic CD19/BCMA-targeted CAR-NK cell product” NCT07144462 ↗ |
| Target | CD19 | “CD19/BCMA-targeted CAR-NK cell product” NCT07144462 ↗ |